Article
Oncology
Xia Li, Qigen Fang, Wei Du, Xu Zhang, Liyuan Dai, Yongming Qiao
Summary: The addition of sintilimab to induction chemotherapy in locally advanced head and neck squamous cell carcinoma patients resulted in a significantly higher objective response rate and longer progression-free survival compared to chemotherapy alone. However, there was no significant difference in overall survival between the two groups. The incidence of grade 3 or higher acute toxicity was similar in both groups.
Article
Otorhinolaryngology
L. Lopez, P. Garcia-Cabo, J. L. Llorente, F. Lopez, J. P. Rodrigo
Summary: This study aims to describe the outcomes of salvage surgery in patients with locally advanced head and neck squamous cell carcinoma. The results showed that patients with nodal persistence/recurrence have a poor prognosis, but in a substantial number of patients, the disease can be controlled after salvage neck dissection.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Yen-Hao Chen, Chih-Yen Chien, Tai-Ling Huang, Tai-Jen Chiu, Yu-Ming Wang, Fu-Min Fang, Shau-Hsuan Li
Summary: This study aimed to investigate the role of p16 cytoplasmic staining in prognosis of head and neck squamous cell carcinoma (HNSCC). A total of 195 HNSCC patients who received TPF induction chemotherapy followed by chemoradiotherapy were enrolled. The study found that low expression of p16 cytoplasmic staining and primary tumor location in the oral cavity were both independent prognostic factors for treatment response and survival in HNSCC.
Review
Oncology
Susumu Okano, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Tomoya Yokota, Yoshinori Imamura, Yosuke Ariizumi, Tetsuo Akimoto, Ryuichi Hayashi
Summary: Induction chemotherapy is a treatment option for head and neck squamous cell carcinoma, with the current standard regimen being docetaxel, cisplatin and 5-FU. Careful consideration should be given to factors such as toxicity, cost, and treatment duration when choosing this therapy, and there is still no consensus on the best treatment option after induction chemotherapy.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yujia Zhu, Jing Wen, Qiaoqiao Li, Baoqing Chen, Lei Zhao, Shiliang Liu, Yadi Yang, Sifen Wang, Yingxin Lv, Jibin Li, Li Zhang, Yonghong Hu, Mengzhong Liu, Mian Xi
Summary: This study investigated the efficacy and safety of combining toripalimab with definitive chemoradiotherapy in patients with locally advanced oesophageal squamous cell carcinoma, and explored potential biomarkers. The results showed that the combination therapy demonstrated promising activity and acceptable toxicity, indicating the need for further investigation.
Article
Medicine, General & Internal
Dashan Ai, Jinjun Ye, Shihong Wei, Yunhai Li, Hui Luo, Jianzhong Cao, Zhengfei Zhu, Weixin Zhao, Qin Lin, Huanjun Yang, Xiangpeng Zheng, Jialiang Zhou, Guang Huang, Ling Li, Jiancheng Li, Zhi Zhang, Guoren Zhou, Dayong Gu, Mingyu Du, Miao Mo, HuiXun Jia, Zhen Zhang, Kuaile Zhao
Summary: This randomized clinical trial compared the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma (ESCC). The results showed that paclitaxel plus fluorouracil did not have superior overall survival compared to paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in locally advanced ESCC. The cisplatin group had higher rates of hematologic and gastrointestinal toxic effects.
Article
Oncology
Meng-Che Hsieh, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Shyh-An Yeh, Tzer-Zen Hwang
Summary: The primary tumor location has a significant impact on survival in patients with locally advanced head and neck squamous cell carcinoma treated with induction chemotherapy. Patients with oral cavity cancer had inferior overall survival in the induction chemotherapy group compared to the concurrent chemoradiotherapy group, while patients with non-oral cavity cancer had superior overall survival in the induction chemotherapy group.
Article
Oncology
Glenn J. Hanna, Anne O'Neill, Kee-Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert Haddad
Summary: This study investigated the use of dual immune-checkpoint inhibition in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN) before and after surgery. The results showed a promising response rate and suggests further evaluation of this strategy.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Morena Fasano, Ida D'Onofrio, Maria Paola Belfiore, Antonio Angrisani, Valentina Caliendo, Carminia Maria Della Corte, Mario Pirozzi, Sergio Facchini, Marianna Caterino, Cesare Guida, Valerio Nardone, Alfonso Reginelli, Salvatore Cappabianca
Summary: This review discusses the role of clinical management, geriatric evaluation, and therapeutic approaches in elderly patients with head and neck squamous cell carcinoma (HNSCC). Elderly HNSCC patients are often frail with multiple comorbidities and may receive suboptimal treatment. The review summarizes different strategies for the clinical management of elderly HNSCC patients.
Article
Otorhinolaryngology
Wataru Okano, Ryuichi Hayashi, Kazuto Matsuura, Takeshi Shinozaki, Toshifumi Tomioka
Summary: The study indicates that targeted neck dissection (ND) after definitive chemoradiotherapy is an effective intervention for patients with cervical disease recurrence, showing promising survival rates and control rates.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Oncology
Kimberley L. Kiong, Christopher M. K. L. Yao, Fang-Yu Lin, Diana Bell, Renata Ferrarotto, Randal S. Weber, Carol M. Lewis
Summary: A study found that a longer time to surgery (≥34 days) after neoadjuvant chemotherapy in head and neck squamous cell carcinoma patients leads to significantly worse distant metastasis-free rate and disease-free survival rate, but no significant differences in overall survival and locoregional recurrence rate.
Article
Multidisciplinary Sciences
Shiliang Liu, Liling Luo, Lei Zhao, Yujia Zhu, Hui Liu, Qiaoqiao Li, Ling Cai, Yonghong Hu, Bo Qiu, Li Zhang, Jingxian Shen, Yadi Yang, Mengzhong Liu, Mian Xi
Summary: "The results of this study show that the addition of induction chemotherapy to definitive chemoradiotherapy does not improve the response rate or survival of patients with unresectable esophageal squamous cell carcinoma."
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Alexander Ruehle, Sebastian Marschner, Marlen Haderlein, Alexander Fabian, Maria Weymann, Max Behrens, Carolin Senger, Daniel R. Dickstein, Johannes Kraft, Jens von der Gruen, Eric Chen, Todd Aquino-Michaels, Justus Domschikowski, Amanda Bickel, Alev Altay-Langguth, Goda Kalinauskaite, Victor Lewitzki, Konstantinos Ferentinos, Constantinos Zamboglou, Soeren Schnellhardt, Erik Haehl, Simon K. B. Spohn, Eleni Gkika, Daniela Zoeller, Matthias Guckenberger, Volker Budach, Claus Belka, Richard Bakst, Arnulf Mayer, Heinz Schmidberger, Anca-Ligia Grosu, Panagiotis Balermpas, Carmen Stromberger, Nils H. Nicolay
Summary: This study aimed to investigate whether the addition of chemotherapy or cetuximab to radiotherapy improves survival in older adults with HNSCC. The results showed that chemoradiation, but not cetuximab-based bioradiotherapy, was associated with longer overall survival compared to radiotherapy alone. Additionally, the addition of chemotherapy also prolonged progression-free survival. Rating: 8/10.
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Brian J. Park, Austin K. Mattox, Daniel Clayburgh, Mihir Patel, R. Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A. Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T. Lin, William C. Faquin, Peter M. Sadow, Sara Pai
Summary: PD-L1 testing is important for decision-making in HNSCC treatment. Chemoradiation therapy has a significant impact on PD-L1 expression, especially when using a cut-off of CPS >= 20 and >= 50. Oral cavity cancer shows higher discordance rates in local and regional recurrence, suggesting the need for repeat biopsy.
Letter
Pharmacology & Pharmacy
Daniel Rosas, Luis E. Raez
AMERICAN JOURNAL OF THERAPEUTICS
(2020)
Review
Oncology
Christian Rolfo, Andres F. Cardona, Massimo Cristofanilli, Luis Paz-Ares, Juan Jose Diaz Mochon, Ignacio Duran, Luis E. Raez, Alessandro Russo, Jose A. Lorente, Umberto Malapelle, Ignacio Gil-Bazo, Eloisa Jantus-Lewintre, Patrick Pauwels, Tony Mok, Maria Jose Serrano
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2020)
Article
Oncology
Rossana Ruiz, Marco Galvez-Nino, Ebert Poquioma, Abel Limache-Garcia, Edgar Amorin, Mivael Olivera, Natalia Valdiviezo, Juan M. Trejo, Adela Heredia, Gustavo Sarria, Alfredo Aguilar, Luis Raez, Silvia P. Neciosup, Henry L. Gomez, Eduardo Payet, Luis Mas
JOURNAL OF THORACIC ONCOLOGY
(2020)
Article
Oncology
Matthew D. Hellmann, Pasi A. Janne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, Susan Brouwer, Serap Sankoh, Lei Wang, David Tamang, Emmett Schmidt, Michael L. Meyers, Suresh S. Ramalingam, Elaine Shum, Peter Ordentlich
Summary: In patients with NSCLC who had previous experience with PD-(L)1, the combination of entinostat and pembrolizumab did not meet the primary response rate endpoint but provided a clinically meaningful benefit, with 9% of patients showing objective response. No new toxicities, including immune-related adverse events, were observed.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Arturo Loaiza-Bonilla, Al B. Benson, Axel Grothey, Misagh Karimi, Samuel J. Klempner, Daniel Lin, Reshma Mahtani, Heloisa P. Soares
Summary: Genomic testing is becoming crucial in cancer diagnosis and treatment decision-making, especially in gastrointestinal cancers like colorectal cancer. Advancements in technology allow for noninvasive screening for CRC through blood or stool tests, while also providing prognostic information and guiding therapy selection.
Article
Public, Environmental & Occupational Health
Jesus C. Fabregas, Benjamin T. Carter, Jose Lutzky, William Russell Robinson, Jeannine M. Brant
Summary: The study suggests that patients diagnosed with melanoma in Medicaid Expansion States are less likely to be diagnosed with Stage IV melanoma, with a more pronounced effect among Black minorities.
JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES
(2022)
Review
Oncology
Jesus C. Fabregas, Brian Ramnaraign, Thomas J. George
Summary: Colon cancer requires better screening and treatment options, especially with the rising incidence in the young population. Circulating tumor DNA and immunotherapy offer potential advancements in treatment, but face challenges in broader efficacy. Targeted therapies are a viable option for patients with poor prognosis.
CLINICAL COLORECTAL CANCER
(2022)
Article
Gastroenterology & Hepatology
Ibrahim Nassour, Austin Parrish, Lucy Baptist, Sarah Voskamp, Komal Handoo, Sherise Rogers, Jesus Fabregas, Thomas George, Kathryn Hitchcock, Alessandro Paniccia, Steven Hughes
Summary: The use of neoadjuvant systemic therapy in the treatment of pancreatic cancer has surpassed the traditional standard of upfront surgery followed by adjuvant therapy, indicating a national shift in clinical management of the disease.
Meeting Abstract
Oncology
Stephanie Boisclair, Shenae Samuels, Luis E. Raez, Delia A. Wietecha, Alejandro Lopez Cohen, Arjun Khunger, Kelly King, Candice Sareli, Jorges Adames, Jessica Jacques, Mathew Salzberg, Brian Hunis, Michel Vulfovich, Atif M. Hussein
Meeting Abstract
Oncology
Stephanie Boisclair, Shenae Samuels, Arjun Khunger, Delia A. Wietecha, Alejandro Lopez Cohen, Kelly King, Candice Sareli, Jessica Jacques, Mathew Salzberg, Michel Vulfovich, Brian Hunis, Luis E. Raez, Atif M. Hussein
Review
Oncology
Jorge J. Garcia, Luis E. Raez, Daniel Rosas
TRANSLATIONAL LUNG CANCER RESEARCH
(2020)
Meeting Abstract
Oncology
Hina Khan, Harish Saiganesh, Adam J. Olszewski, Yasmine Baca, Michaela Kastura, John Vatkevich, Nimesh Patel, Humera Khurshid, Ariel E. Birnbaum, Stephen Liu, Hirva Mamdani, Chul Kim, Ari M. Vanderwalde, Luis E. Raez, Mark A. Socinski, Gilberto Lopes, Sachin Gopalkrishna Pai, Jorge J. Nieva, Christopher G. Azzoli, Howard Safran
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Oncology
Stephen Liu, Ari M. Vanderwalde, Hirva Mamdani, Luis E. Raez, Yasmine Baca, Joanne Xiu, Wolfgang Michael Korn, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto Lopes, Alexander Spira, Julia Judd, Edward S. Kim, Hossein Borghaei
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Oncology
Meera Patel, Andrew Elliott, Stephen Liu, Chul Kim, Luis E. Raez, Rebecca Feldman, Sachin Gopalkrishna Pai, Antoinette J. Wozniak, Misako Nagasaka, Gilberto Lopes, Alexander Spira, Edward S. Kim, Wolfgang Michael Korn, Hirva Mamdani
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Review
Respiratory System
Andres F. Cardona, Oscar Arrieta, Alejandro Ruiz-Patino, Carolina Sotelo, Nataly Zamudio-Molano, Zyanya Lucia Zatarain-Barron, Luisa Ricaurte, Luis Raez, Marco Polo Peralta alvarez, Feliciano Barron, Leonardo Rojas, Christian Rolfo, Niki Karachaliou, Miguel Angel Molina-Vila, Rafael Rosell
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2020)